Corcept Therapeutics Incorporated (CORT) announced that it has completed enrollment in the phase III ROSELLA study, which is evaluating its lead pipeline candidate, relacorilant, in combination with Abraxane (nab-paclitaxel) for treating patients with recurrent, platinum-resistant ovarian cancer.The primary endpoint of this pivotal phase III study is progression-free survival, while overall survival is a key secondary endpoint. Progression-free survival data from the ROSELLA study is expected by 2024-end.Pr ...

MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in ROSELLA, a pivotal Phase 3 trial of its proprietary selective cortisol modulator relacorilant combined with nab-paclitaxel in patients with recurrent, p ...

Corcept Therapeutics Incorporated (CORT) reported fourth-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 25 cents. The company reported earnings of 14 cents per share in the year-ago quarter.Revenues increased 31% year over year to $135.4 million. The figure beat the Zacks Consensus Estimate of $130 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Quarter in DetailRevenues from Korlym met our model estimate of $135.4 million.Rese ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President, Corcept Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Tru ...

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2023. Financial Results Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022Full year ...

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing's syndrome (hypercortisolism) in patients with difficult-to-control type 2 diabetes. With a pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdiction of incorporation or organization ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Corcept Therapeutics (CORT) , which belongs to the Zacks Medical - Drugs industry.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 46.97%, on average, in the last two quarters.For the last reported quarter, Corcept came out with earnings of $0.28 per sh ...

MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vie ...

Financial Data and Key Metrics Changes - The company's revenue for Q3 2023 was $123.6 million, representing a 22% increase compared to the same quarter last year [47] - Net income for the quarter was $31.4 million, or $0.28 per share [47] - Cash and investments as of September 30th totaled $414.8 million, an increase of $51.5 million during the quarter [47] - The revenue guidance for 2023 has been raised to a range of $470 million to $480 million, up from the previous range of $455 million to $470 million [52] Business Line Data and Key Metrics Changes - The growth in revenue was driven by a 12% increase in volume and a 9% increase in price for Korlym [79] - The company is experiencing a mix of new prescribers and repeat prescriptions from existing physicians, contributing to the growth in Korlym sales [82] Market Data and Key Metrics Changes - There is an increasing recognition among physicians that hypercortisolism is more common than previously assumed, leading to more screenings and diagnoses [80] - The CATALYST study is expected to provide further evidence supporting the prevalence of hypercortisolism, which could enhance the treatment landscape for Cushing's syndrome [51] Company Strategy and Development Direction - The company is focused on expanding its sales force and improving the effectiveness of its team, with a target of increasing the sales force from mid-60s to about 75 [18] - The company is advancing multiple clinical development programs, including GRACE, GRADIENT, CATALYST, ROSELLA, and DAZALS studies, with significant milestones expected in 2024 [35][43] - The company is optimistic about the growth potential of its Cushing's syndrome business and the broader applications of cortisol modulation in various diseases [73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their case against Teva Pharmaceuticals regarding patent infringement, which is expected to be resolved by mid-2025 [32] - The management anticipates continued growth in the Cushing's syndrome market as more physicians become aware of the condition and its treatment options [51] Other Important Information - The company has robust intellectual property protections for both Korlym and relacorilant, with protections extending through 2037 and beyond 2040, respectively [25][26] - The company introduced a new executive team member, Monica Toledo, who will focus on emerging markets such as ALS and NASH [74] Q&A Session Summary Question: Can you provide specifics on the year-over-year volume growth for Korlym? - The company reported a 22% growth, with 12% driven by volume and 9% by price [79] Question: What does the increase in screening for hypercortisolism mean for future growth? - The recognition that hypercortisolism is more common is expected to sustain growth as more patients are diagnosed and treated [80] Question: Can you elaborate on the GRACE study and its primary endpoint? - The GRACE trial is evaluating dosing escalation and aims to show significant improvement in patients with Cushing's syndrome [85]